Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenoviridae Infections × enadenotucirev × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 2 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrent Platinum Resistant Ovarian Cancer 1 Rectal Neoplasms 1 Neoplasm Metastasis 1 Carcinoma 1 Adenoviridae Infections 1

Interventions

Gemcitabine 2 Cell Count 2 ziprasidone 1 valrubicin 1 tretazicar 1 pembrolizumab 1 liposomal doxorubicin 1 fludarabine phosphate 1 fludarabine 1 enadenotucirev 1 atezolizumab 1 Zolpidem 1 Warfarin 1 Vecuronium Bromide 1 Vancomycin 1 Vaccines 1 Tumor Necrosis Factor-alpha 1 Tranexamic Acid 1 Tobramycin 1 Spironolactone 1 Sevelamer 1 Rocuronium 1 Radiotherapy 1 Piperacillin, Tazobactam Drug Combination 1 Pentobarbital 1 Oxycodone 1 Oncolytic Virotherapy 1 Nifedipine 1 Nafcillin 1 Molindone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03916510 2025-02-06

CEDAR

University of Oxford

Phase 1 Completed

12 enrolled 13 charts

Gastrointestinal

Adenoviridae Infections, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡